Axsome Therapeutics (AXSM) Stock Price & Analysis
Score
AI Analysis
SnapshotAxsome Therapeutics is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 65/100) in Biotechnology. Under the hood: revenue compounding ~183% annually over recent years. Street targets still imply ~97% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Axsome Therapeutics, Inc. (AXSM) last printed $141.69. Equity value is $7.45B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $50.04M | $270.6M | $385.69M | $638.5M |
About
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.